STRIDE Pivotal Trial of CereVasc’s eShunt System Completes Enrollment

June 24, 2026—CereVasc, Inc. announced it has completed patient enrollment in the STRIDE pivotal trial, which is evaluating the company’s investigational eShunt system in patients with normal pressure hydrocephalus (NPH). Patient enrollment was conducted at 32 clinical sites in the United States, Canada, and Argentina.

According to CereVasc, STRIDE is a prospective, multicenter, randomized controlled trial comparing the safety and effectiveness of eShunt system head-to-head against the current standard of care, the ventriculoperitoneal shunt, in elderly patients with NPH. The STRIDE results are intended to serve as the clinical basis for CereVasc’s anticipated premarket approval submission to the FDA.

The study is now progressing through remaining treatment and follow-up activities for consented patients, keeping the company on track toward topline data and continued progress through the premarket approval process, advised the company.

Charles Matouk, MD, with Yale Neurosurgery in New Haven, Connecticut, commented on the milestone in CereVasc’s press release.

“Reaching full enrollment is an important achievement for STRIDE and reflects the clinical community’s commitment to studying less invasive treatment options for patients with NPH,” stated Dr. Matouk. “The study will continue to follow its protocol as previously consented patients complete the remaining clinical steps.”